Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adrenergic Agonist

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Adrenergic Agonist. Displaying page 1 of 1.
    EudraCT Number: 2021-000731-31 Sponsor Protocol Number: NL76746.068.21 Start Date*: 2021-10-14
    Sponsor Name:Maastricht University
    Full Title: Targeting the beta-2 adrenergic pathway to improve skeletal muscle glucose uptake in obese humans
    Medical condition: Type 2 diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004245-16 Sponsor Protocol Number: NL67646.068.18 Start Date*: 2019-04-16
    Sponsor Name:Maastricht University
    Full Title: Targeting the beta-2 adrenergic pathway to improve skeletal muscle glucose uptake in healthy humans
    Medical condition: Type 2 diabetes
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-000313-20 Sponsor Protocol Number: 1208094 Start Date*: 2013-06-14
    Sponsor Name:CHU de Saint-Etienne
    Full Title: Evaluation of the biological response to clopidogrel in patients with ischemic stroke: role of platelet alpha2-adrenergic receptors
    Medical condition: Ischemic stroke
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004852 10023027 Ischaemic stroke NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002949-32 Sponsor Protocol Number: SPHERE-HF Start Date*: 2017-03-22
    Sponsor Name:Fundació Clínic per la recerca Biomédica [...]
    1. Fundació Clínic per la recerca Biomédica
    2. CNIC
    Full Title: β3 adrenergic agoniSt treatment in chronic Pulmonary HypERtEnsion secondary to heart failure: a randomized placebo-controlled phase 2 clinical trial
    Medical condition: Pulmonary Hypertension secondary to heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-003533-10 Sponsor Protocol Number: CIGE025ABR01 Start Date*: 2016-02-16
    Sponsor Name:Novartis
    Full Title: A Randomized, Open-label, Multicenter Study to Evaluate the Effect of Xolair (Omalizumab) as Add-on Therapy to Inhaled Corticosteroid + Long-Acting Beta Agonist in Fixed or Flexible Dosing Compared...
    Medical condition: Severe persistent allergic asthma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-001160-36 Sponsor Protocol Number: 2008-1 Start Date*: 2009-06-04
    Sponsor Name:Imperial College London
    Full Title: A trial of Guanfacine, an alpha 2 adrenergic agonist, for Spatial Neglect and Impaired Vigilance following Stroke and Focal Brain Damage
    Medical condition: Spatial Neglect following Hemispheric stroke and focal brain injury
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10050400 Vigilance decreased LLT
    14.0 10029205 - Nervous system disorders 10029289 Neurologic neglect syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002812-27 Sponsor Protocol Number: CEP-1347-201 Start Date*: 2005-05-04
    Sponsor Name:deCODE genetics ehf.
    Full Title: A prospective, randomised, double-blind, placebo-controlled, parallel group dose ranging study in asthma patients in Iceland to assess the safety, tolerability and efficacy of the MLK inhibitor, CE...
    Medical condition: Asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004709-53 Sponsor Protocol Number: 911 Start Date*: 2005-12-05
    Sponsor Name:Merck Sharp & Dohme OÜ
    Full Title: A Multicenter, Double-Blind, Randomized, Cross-Over Design Study to Evaluate the Effect of Montelukast vs. Salmeterol on the Inhibition of Excercise-Induced Bronchoconstriction in Asthmatic Patient...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    8.0 10003553 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed) ES (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-003289-29 Sponsor Protocol Number: ACT15102 Start Date*: 2018-06-19
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 12-week Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500 and the Coadministration...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005540-34 Sponsor Protocol Number: CLR_14_12 Start Date*: 2016-07-19
    Sponsor Name:Sun Pharma Advanced Research Company, Ltd. (SPARC)
    Full Title: A Multi-Center, Investigator-Masked, Randomized, Crossover, Equivalence Study of the Safety and Efficacy of Once Daily Brimonidine Tartrate 0.35% Ophthalmic Suspension Compared with Brimonidine Tar...
    Medical condition: Open-angle glaucoma, chronic angle closure glaucoma with patent iridotomy, pseudoexfoliation, pigment dispersion, or ocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    19.1 10015919 - Eye disorders 10018304 Glaucoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-019798-13 Sponsor Protocol Number: MB102-077 Start Date*: 2011-03-04
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with Inadequately Co...
    Medical condition: Type 2 diabetes with inadequate glycemic control and inadequately controlled hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    14.1 100000004866 10066860 Uncontrolled hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) FI (Completed) DK (Completed) IE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-004893-14 Sponsor Protocol Number: ASR115645 Start Date*: 2016-08-03
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: A Randomised, Multi-centre, Double-blind, Double-dummy, two way cross-over, twelve weeks noninferiority study to evaluate the efficacy, safety and tolerability of combination dry powder Fluticasone...
    Medical condition: Asthma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-005280-31 Sponsor Protocol Number: INHALAVID Start Date*: 2021-04-21
    Sponsor Name:Fundació Eurecat
    Full Title: Phase IV, single-center, randomized and open-label study to evaluate the impact of early treatment with a combination of an inhaled corticosteroid and a long-acting β2 adrenergic agonist (budesonid...
    Medical condition: Enfermedad en pacientes vulnerables con COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002490-26 Sponsor Protocol Number: ACT17208 Start Date*: 2021-10-08
    Sponsor Name:Sanofi aventis recherche et developpement
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group, 12 week Proof-of-Concept (PoC) study to assess the efficacy, safety, and tolerability of rilzabrutinib in participants with moderate-...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Completed) HU (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001580-39 Sponsor Protocol Number: C38072-AS-30027 Start Date*: 2015-10-30
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Phase 3, 24-Week Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Reslizumab Subcutaneous Dosing (110 mg Every 4 weeks) in Patients with Oral Corticosteroid Dependen...
    Medical condition: Asthma & elevated blood Eosinophils
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) BE (Completed) ES (Completed) IT (Completed) NL (Completed) PL (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 01 20:58:42 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA